A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
A phase 2 trial of Anvumetostat in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.
Overview
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) is a phase 2 interventional study registered as NCT06593522 by Amgen, with 61 participants enrolled, started 2024-12-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: anvumetostat.
Similar pages
not linked directly; found by shared links- TrialA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Shares Anvumetostat, Amgen and the tag pipeline.
- TrialStudy of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Shares Amgen, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Shares Amgen and the tag pipeline.
- TrialA Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Shares Amgen and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.